BioInvent reports net revenues of SEK 63.1M for January – June 2010 period
BioInvent reports net revenues of SEK 63.1M for January – June 2010 period
BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company’s partner, ThromboGenics, will now prioritise securing a development …
Read more on News-Medical-Net